These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15818507)

  • 21. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
    Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
    Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
    Patel M; McCully C; Godwin K; Balis FM
    J Neurooncol; 2003 Feb; 61(3):203-7. PubMed ID: 12675312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.
    Kim H; Likhari P; Parker D; Statkevich P; Marco A; Lin CC; Nomeir AA
    J Pharm Biomed Anal; 2001 Jan; 24(3):461-8. PubMed ID: 11199225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
    Schoemaker NE; Mathôt RA; Schöffski P; Rosing H; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):514-7. PubMed ID: 12451480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; Hommes DW; van Hoek B
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1447-54. PubMed ID: 17848182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
    Devineni D; Klein-Szanto A; Gallo JM
    Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
    Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The simulation of UV spectroscopy and electronic analysis of temozolomide and dacarbazine chemical decomposition to their metabolites.
    Khalilian MH; Mirzaei S; Taherpour AA
    J Mol Model; 2016 Nov; 22(11):270. PubMed ID: 27783227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited sampling strategies to estimate the area under the concentration-time curve. Biases and a proposed more accurate method.
    Tsuruta H; Fukumoto M; Bax L; Kohno A; Morishita Y
    Methods Inf Med; 2012; 51(5):383-94. PubMed ID: 22614791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
    Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
    Ma J; Li S; Reed K; Guo P; Gallo JM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
    Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
    Furth AF; Mandrekar SJ; Tan AD; Rau A; Felten SJ; Ames MM; Adjei AA; Erlichman C; Reid JM
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):39-45. PubMed ID: 17909811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.